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Abstract
Objective: To determine whether 5 single nucleotide polymorphisms (SNPs) associate with ALS in 3 different populations.
We also assessed the contribution of genotype to angiogenin levels in plasma and CSF.
Methods: Allelic association statistics were calculated for polymorphisms in the ANG gene in 859 patients and 1047 controls
from Sweden, Ireland and Poland. Plasma, serum and CSF angiogenin levels were quantified and stratified according to
genotypes across the ANG gene. The contribution of SNP genotypes to variance in circulating angiogenin levels was
estimated in patients and controls.
Results: All SNPs showed association with ALS in the Irish group. The SNP rs17114699 replicated in the Swedish cohort. No
SNP associated in the Polish cohort. Age- and sex-corrected circulating angiogenin levels were significantly lower in patients
than in controls (p,0.001). An allele dose-dependent regulation of angiogenin levels was observed in controls. This
regulation was attenuated in the ALS cohort. A significant positive correlation between CSF plasma angiogenin levels was
present in controls and abolished in ALS.
Conclusions: ANG variants associate with ALS in the Irish and Swedish populations, but not in the Polish. There is evidence
of dysregulation of angiogenin expression in plasma and CSF in sporadic ALS. Angiogenin expression is likely to be
important in the pathogenesis of ALS.
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Introduction
Angiogenin is the 14.1-kDa product of the hypoxia responsive
gene ANG on chromosome 14. We have shown previously that
mutations in ANG are associated with amyotrophic lateral sclerosis
(ALS), and that ANG mutations predict loss of RNAse and
angiogenic function [1]. Moreover, recent studies have suggested
that angiogenin is an important neurodevelopmental protein with
neuroprotective properties, and that mutant ANG impairs neurite
outgrowth. [2–4].
Angiogenin is functionally similar to vascular endothelial
growth factor (VEGF), altered regulation of which has also been
associated with ALS [5,6]. ‘At risk’ promoter haplotypes in
VEGF, which predict reduced expression of bioavailable
isoforms, have been described in some European ALS popula-
tions [7] and combined with evidence from animal models, the
data suggest that VEGF isoforms have a neuromodulatory and
neuroprotective role in the CNS. Despite the functional similarity
between angiogenin and VEGF, there have been few studies to
date that have investigated angiogenin expression and regulation
in ALS.
We have recently shown that serum angiogenin levels in ALS
differ from controls [8]. The patterns of plasma and cerebrospinal
fluid (CSF) angiogenin expression have not previously been
investigated, and there have been no studies to determine whether
ANG haplotypes modulate protein expression, as is the case with
VEGF. We have sought to determine (i) whether angiogenin is
detectable in CSF, (ii) whether there is a consistent relationship
between plasma and CSF angiogenin levels, (iii) whether genetic
variations in the ANG locus control angiogenin expression, and (iv)
whether, as has been reported for VEGF [9–11], there is a
dysregulation of angiogenin in sporadic ALS.
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Methods
Participants
DNA and serum samples were drawn from Irish and Polish ALS
patients; DNA, plasma and cerebrospinal fluid (CSF) samples were
drawn from Swedish ALS patients. Unrelated control subjects with
no family history of ALS were sampled from the same populations.
The numbers of participants available in the three study
populations and their demographics are detailed in figure 1. All
patients fulfilled the El Escorial criteria for clinically definite or
probable ALS [12]. Patients with atypical phenotypes and Swedish
patients with mutations in the SOD1 gene were excluded.
Informed written consent was obtained from all participants and
the study was approved by the ethics committees in Beaumont
Hospital, Umeå University and the Jagelonian Institute.
SNP genotyping
Using data from the CEPH panel of the International HapMap
Project [13], 5 informative haplotype-tagging single nucleotide
polymorphisms (htSNPs) were selected covering the ANG gene
with inter-marker r2 below 0.8 and minor allele frequency above
5%. These htSNPs are detailed in table 1. Genotyping across these
five htSNPs was performed commercially by KBiosciences (Herts,
UK) using KASPar assays with standard quality-control criteria
(genotypes formed three distinct clusters, water controls were
negative and minor allele frequency was above 5%).
Quantification of angiogenin in CSF, plasma and serum
Serum and plasma were isolated from peripheral blood
according to standard protocols. Since angiogenin has not been
shown to have any interaction partners in the blood, plasma and
serum angiogenin concentrations were considered to be compa-
rable. Samples were stored at 280uC until assay. Angiogenin
concentration was measured by enzyme-linked immunosorbent
assay (ELISA) according to manufacturer’s guidelines (Quantikine
Duoset, R&D Systems, Abingdon, UK). All samples were assayed
in duplicate and calibrated against serially diluted standards of
known mass. Pooled CSF and plasma quality control (QC)
samples were both assayed in duplicate on each mitrotitre plate,
setting the precision of the assay across all microtitre plates. An
Figure 1. Numbers of individuals and demographics of the three study populations. Error values for mean ages represent standard
deviation.
doi:10.1371/journal.pone.0015402.g001
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inter-assay coefficient of variation (CV) of 6% and 8% was
obtained for the high and low plasma QC respectively. An inter-
assay CV of 9% was obtained for the CSF QC.
Statistical analysis
Unless otherwise stated, all statistical analyses were performed
using the R statistical programming environment [14]. Assessment
of allele frequencies were conducted using the computer
programmes Haploview [15] and PLINK [16]. Allelic association
statistics were calculated using the chi-squared test, with correction
for multiple testing by replication in the three populations.
Haplotype blocks were defined as a group of htSNPs whose upper
95% confidence bound for D’ exceeded 98% with the lower
bound above 70% [17] and a haplotype was examined if it
occurred in more than 1% of individuals. Haplotypes were tested
for association with ALS risk using the chi-squared test.
The data for angiogenin levels were assessed for the reported
influence of age and sex [18]. Using data pooled from cases and
controls in all three populations, angiogenin levels were regressed
against age and sex and an outlier was identified and removed if its
studentized residual exceeded the critical t statistic for the group’s
Bonferroni-corrected 5% significance threshold. The regression
analysis was then re-iterated until no further outliers could be
identified. Four Swedish plasma values and four Swedish CSF
values were removed this way. The resulting linear models were
used to adjust the values in the respective groups based on age and
sex. The influences of genotypes across the five htSNPs were then
assessed by analysis of variance (ANOVA) for each htSNP and the
differences between case and control angiogenin levels for each
genotype were assessed for statistical significance using the Mann-
Whitney-Wilcoxon test. Finally, using data from the Swedish
population, corrected plasma angiogenin levels were assessed for
correlation with corrected CSF angiogenin levels in ALS patients
and in controls independently.
Results
ANG SNP and haplotype association
The mean genotyping call rate across all htSNPs in the three
populations was 98.4%. No htSNP deviated significantly from
Hardy-Weinberg equilibrium in any study population. The results
for the allelic association tests for the five htSNPs are shown in
table 1. Linkage disequilibrium (LD) between htSNPs is shown in
Figure S1. All five htSNPs showed association with risk for ALS in
the Irish study group, with one htSNP, rs17114699, replicating in
the Swedish population (pIrish = 0.03; pSwedish = 0.001). No htSNP
showed association in the Polish population. A haplotype block
was identified in all three populations, incorporating SNPs
rs9322855, rs8004382 and rs4470055. The AAG and CGA
haplotypes at these three SNPs associated with ALS in the Irish
data, while the AGG haplotype showed strong association with
ALS in the Swedish data (table 2).
Plasma, serum and CSF angiogenin levels
Age and sex both had a significant effect on angiogenin levels in
plasma/serum and in CSF (P(.|t|) ,0.0001 for all covariates).
Using data pooled from the three populations and after correcting
for age and sex, angiogenin levels were significantly lower in ALS
patients than in controls in plasma/serum (mean 6 SD =
438.26112.2 ng/ml for the ALS group and 467.66105.4 ng/ml
for controls; p = 0.001, Mann-Whitney-Wilcoxon test) and in CSF
(mean 6 SD = 5.58261.754 ng/ml for the ALS group and
6.19761.987 ng/ml for controls; p = 0.01, Mann-Whitney-Wil-
coxon test). Angiogenin levels did not differ significantly depending
on whether they were measured from serum or plasma (p = 0.93;
Figure S2). There was a significant positive correlation (p,0.0001,
Pearson product-moment correlation) between corrected CSF
angiogenin levels and corrected plasma angiogenin levels in
controls, whereas in ALS patients (p = 0.21) the observed
correlation was attenuated (figure 3; r2control = 0.13, r
2
ALS = 0.011).
Contribution of SNP genotypes to angiogenin levels
Levels varied considerably around the fitted models (multiple
r2serum/plasma = 0.074; multiple r
2
CSF = 0.16). ANOVA was used to
assess the contribution of genotype at each htSNP to the overall
variance in the data and the Mann-Whitney-Wilcoxon test was
used to assess the differences between corrected plasma/serum
levels in ALS patients and controls for each SNP, separated by
genotype. Data were analysed both as independent populations
and also as a pooled dataset. The results of these tests, along with
the group means, are reported in figure 2.
In the large Swedish dataset, an allele dose-dependent
regulation of plasma angiogenin was readily observable for all
SNPs in controls and perturbation of this pattern was seen in ALS
patients at SNPs rs8004382 and rs9322855. These findings are
reflected in the pooled dataset. Only at SNP rs11701 was a
significant contribution of genotype to the variance in controls
observable in all three populations; however, in the pooled dataset
genotypes at every SNP except rs9322855 were shown to
contribute significantly to variance in controls. No SNP contrib-
uted significantly to variance in ALS patients in the pooled data,
however this was observed at rs11701 in the Polish dataset.
Table 1. Allele frequencies and SNP association statistics in the three populations.
SNP Alleles IRELAND SWEDEN POLAND
RA RA freq Allelic association RA RA freq Allelic association RA RA freq Allelic association
ALS;ctrl p OR ALS;ctrl p OR ALS;ctrl p OR
rs9322855 A.C C 0.50; 0.59 0.003* 1.57 A 0.56; 0.52 0.13 0.85 A 0.55; 0.55 0.92 0.99
rs8004382 G.A G 0.57; 0.47 0.007* 1.50 G 0.55; 0.52 0.46 0.92 G 0.55; 0.52 0.46 0.92
rs4470055 G.A A 0.29; 0.22 0.03* 1.47 A 0.25; 0.24 0.66 1.06 G 0.75; 0.72 0.36 0.88
rs17114699 G.T T 0.16; 0.11 0.03* 1.53 T 0.14; 0.08 0.001* 1.78 G 0.89; 0.87 0.68 0.93
rs11701 T.G G 0.18; 0.10 0.006* 1.88 G 0.13; 0.13 0.69 1.07 G 0.13; 0.10 0.14 1.3
RA, risk allele; OR, odds ratio.
*Significant p-value.
doi:10.1371/journal.pone.0015402.t001
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Table 2. Haplotype frequencies and association statistics in the three populations.
Haplotype IRELAND SWEDEN POLAND
Freq (ALS;ctrl) p Permuted p Freq (ALS;ctrl) p Permuted p Freq (ALS;ctrl) p Permuted p
AAG 0.45; 0.53 0.024* 0.13 0.46; 0.47 0.64 0.99 0.453; 0.474 0.4498 0.95
CGA 0.29; 0.22 0.023* 0.12 0.25; 0.25 0.68 1.00 0.256; 0.279 0.3627 0.90
CGG 0.18; 0.16 0.43 0.94 0.18; 0.24 0.027 0.16 0.193; 0.172 0.3424 0.88
AGG 0.07; 0.08 0.55 0.98 0.097; 0.045 ,0.0001* 0.0006* 0.099; 0.075 0.1311 0.51
*Significant p-value.
doi:10.1371/journal.pone.0015402.t002
Figure 2. Mean corrected serum or plasma angiogenin concentrations as a function of ANG htSNP genotype. ALS patients are shown in
red and controls are shown in blue. Significant differences between ALS patients and controls are denoted by solid lines and significant F-statistics
within groups are denoted by asterisks. Error bars are standard error of the mean. Numbers of observations for each genotype at each SNP are
indicated in the table below each plot.
doi:10.1371/journal.pone.0015402.g002
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Discussion
This study confirms the previously observed association between
ANG variants and ALS in the Irish population [1], with 5 htSNPs
across the ANG gene showing association with ALS. One htSNP,
rs1711699, replicated in the Swedish cohort, showing strong
association with ALS risk (p = 0.001). We have also demonstrated
that two ANG haplotypes in the Irish and one in the Swedish
associate with ALS, adding strength to the argument that ANG is
implicated in the pathogenesis of sporadic ALS. Although
replication in the Swedish population increases our confidence
in the Irish findings, no htSNP or haplotype associated with ALS
in the Polish population. Similarly, in a recent screen for
replication of findings from the Irish genome-wide association
study for ALS risk [19] using a Polish dataset, the results were
surprisingly uninformative [20]. The failure to replicate in the
Polish population may reflect true population based differences, as
has been recently demonstrated both in population genetics [21]
and with respect to other risk genes in ALS [20]. Together, these
findings suggest that the complex genetics of ALS differ between
the Polish, Swedish and Irish populations.
Figure 2 (notably parts a and c) demonstrates the need for large
datasets when analysing data that vary so substantially by chance.
However, using pooled data we have shown that contribution of
SNP genotypes to variance in angiogenin levels in serum is evident
in neurologically normal individuals, and that this is abolished in
ALS. In controls, this contribution of genotype to variance is allele
dose-dependent. SNP genotypes at rs11701 were observed to
contribute to variance in ALS patients in the Polish; this finding is
consistent with the observation that no ANG SNP or haplotype
associated with ALS in the Polish.
Using the current Irish dataset, we were unable to replicate our
previous finding that serum angiogenin levels are higher in ALS
patients compared to controls [8]. Using our current data pooled
with Swedish and Polish populations, we have shown that
angiogenin levels are in fact significantly lower in ALS patients
than in neurologically normal controls (p,0.001). Moreover, sub-
categorisation of ALS patients and controls by SNP genotypes
maintains the significance of the case-control differences in
angiogenin levels (figure 2).
The differences between the current data and our previous
findings most likely relate to differences in our statistical manage-
ment of the dataset. In the original study we considered the effects of
covariates (age, sex) in ALS patients and controls independently. In
the current analysis, we more correctly assumed that angiogenin
levels in ALS patients would follow the same patterns based on age
and sex as those observed in controls. Thus serum angiogenin levels
were initially regressed against age and sex using combined data
from cases and controls. This methodology permits a more robust
estimate of the influence of age and sex on angiogenin levels, as it
uses approximately twice as many values (541 values) as would be
used if considering cases and controls separately. Indeed, re-analysis
of the current dataset using our previous methodology yielded a
significantly higher mean corrected angiogenin level in cases than in
controls (p,0.0001); we now consider this to be a less accurate
interpretation of the available data.
In neurologically normal controls, plasma angiogenin concen-
tration predicts CSF angiogenin concentration (p,0.0001, figure 3).
We have shown that this correlation is lost in ALS patients (p = 0.21
for patients), which may suggest a tissue-specific dysregulation of
angiogenin expression in ALS. This could be due to a number of
factors, including perturbation of angiogenin transport in ALS,
however an interesting possibility could be micro RNA (miRNA)
regulation of angiogenin expression. Altered miRNA regulation of
progranulin has been reported recently in frontotemporal dementia
[22]. As progranulin is functionally similar to angiogenin, and
frontotemporal dementia is biologically related to ALS [23], a
similar form of altered regulation of angiogenin may apply in ALS.
A search the EBI’s miRBase Sequence Database [24] using the
online Microcosm web application reveals 19 potential miRNA
binding sites in the ANG gene for 24 human miRNAs, some of
which may be preferentially expressed in the central nervous system
[25]. This suggests a possible mechanism for our observed tissue-
specific differences indicating that further investigation of miRNA
regulation of angiogenin is warranted.
In summary, we have confirmed that ANG variants associate with
ALS in the Irish and also in the Swedish. We have also shown that
angiogenin expression is modulated by genetic variation across the
ANG gene in an allele-dose dependent manner, and that this
regulation is disrupted in ALS patients. The finding that plasma
angiogenin level does not predict CSF angiogenin level in ALS
patients suggests a tissue-specific regulation of angiogenin levels that
may be determined by genetic variation [18]. In light of these findings,
further investigation of angiogenin regulation in ALS is justified.
Supporting Information
Figure S1 Linkage disequilibrium between the five ANG
SNPs in the three populations.
Figure S2 Boxplot comparing angiogenin levels mea-
sured in plasma from Swedish individuals (n = 320) and
serum from Irish and Polish individuals (n = 220). The
difference between the two datasets is not statistically significant
(p = 0.93). (PDF)
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Figure 3. Correlation of CSF angiogenin levels with serum
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